LENZ Therapeutics, Inc.
LENZ
$4.73
$0.132.83%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 5.49M | 1.90M | 1.59M | 12.50M | 5.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.49M | 1.90M | 1.59M | 12.50M | 5.00M |
| Cost of Revenue | 280.00K | 1.08M | 418.00K | -- | -- |
| Gross Profit | 5.21M | 825.00K | 1.17M | 12.50M | 5.00M |
| SG&A Expenses | 39.38M | 44.96M | 39.63M | 27.60M | 12.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.66M | 46.04M | 40.05M | 31.39M | 21.86M |
| Operating Income | -34.17M | -44.14M | -38.46M | -18.89M | -16.86M |
| Income Before Tax | -31.92M | -41.49M | -35.89M | -16.70M | -14.41M |
| Income Tax Expenses | 3.00K | -- | 2.00K | -- | 500.00K |
| Earnings from Continuing Operations | -31.92M | -41.49M | -35.90M | -16.70M | -14.91M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -31.92M | -41.49M | -35.90M | -16.70M | -14.91M |
| EBIT | -34.17M | -44.14M | -38.46M | -18.89M | -16.86M |
| EBITDA | -34.06M | -44.02M | -38.36M | -18.76M | -16.84M |
| EPS Basic | -1.02 | -1.32 | -1.16 | -0.59 | -0.53 |
| Normalized Basic EPS | -0.64 | -0.83 | -0.72 | -0.37 | -0.33 |
| EPS Diluted | -1.02 | -1.32 | -1.16 | -0.59 | -0.53 |
| Normalized Diluted EPS | -0.64 | -0.83 | -0.72 | -0.37 | -0.33 |
| Average Basic Shares Outstanding | 31.37M | 31.35M | 31.07M | 28.54M | 28.08M |
| Average Diluted Shares Outstanding | 31.37M | 31.35M | 31.07M | 28.54M | 28.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |